Indeed, MDS patients frequently exhibit mutations in the spliceosome machinery that is thought to be pathogenic, with conditional expression of Srsf2-P95H within murine HSCs sufficient to drive MDS development [201,202]. This evidence concerns the gene SRSF2 and myelodysplastic syndrome.